Prostamax
Also known as: Peptídeo prostático, KEDP
Molecular Identifiers
Overview
Prostatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in prostatic tissue and supports prostate cellular function. Used in short cycles for prostate health protection and maintenance.
KEDP Lys-Glu-Asp-Pro Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in prostatic tissue
- Support for cellular function and prostate homeostasis
- Normalization of prostatic tissue metabolism
- Modulation of prostatic cell proliferation
- Bioregulatory effect on the prostate gland
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day subcutaneously |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Very stable tetrapeptide. Protect from light and moisture. |
Presentations & Preparation
Vials of Prostamax found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Prostamax.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily